Sun’s Mega Deal Explained

How the Scoop Began

Bidding War and Rivals

Strategic Fit and Synergies

Biosimilars Growth Engine

Debt, Financing, Market Reaction

Integration Plan and Timeline

Five Year Success Checklist

Closing Takeaways

India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. Host Anirban Chowdhury talks to ET's pharma expert Vikas Dandekar and associate editor Arijit Barman about why this deal gives Sun Pharma an instant foothold in biosimilars, a dominant position in global women's health, and a portfolio of established brands across 150 countries. With $2.5 billion in combined pre-financing free cash flows, the company looks well-positioned to tackle Organon's inherited debt burden.

<p>India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. Host Anirban Chowdhury talks to ET's pharma expert Vikas Dandekar and associate editor Arijit Barman about why this deal gives Sun Pharma an instant foothold in biosimilars, a dominant position in global women's health, and a portfolio of established brands across 150 countries. With $2.5 billion in combined pre-financing free cash flows, the company looks well-positioned to tackle Organon's inherited debt burden.</p>

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.